364 related articles for article (PubMed ID: 20073129)
1. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
Berger JR; Houff SA; Major EO
MAbs; 2009; 1(6):583-9. PubMed ID: 20073129
[TBL] [Abstract][Full Text] [Related]
2. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
[TBL] [Abstract][Full Text] [Related]
3. Progressive multifocal leukoencephalopathy and newer biological agents.
Berger JR
Drug Saf; 2010 Nov; 33(11):969-83. PubMed ID: 20925435
[TBL] [Abstract][Full Text] [Related]
4. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
Bacchetta F; Mathias A; Schluep M; Du Pasquier R
Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
[TBL] [Abstract][Full Text] [Related]
5. Progressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab.
Berger JR; Houff S
Neurol Res; 2006 Apr; 28(3):299-305. PubMed ID: 16687057
[TBL] [Abstract][Full Text] [Related]
6. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
Cutter GR; Stüve O
Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab and progressive multifocal leukoencephalopathy: highlights of the International Workshop on JC Virus/PML and Multiple Sclerosis, June 3-4, 2005, Philadelphia PA.
Tyler KL; Khalili K
Rev Neurol Dis; 2005; 2(3):144-9. PubMed ID: 16400315
[No Abstract] [Full Text] [Related]
8. Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review.
Sharma K; Tolaymat S; Yu H; Elkhooly M; Jaiswal S; Jena A; Kakara M; Sriwastava S
J Neurol Sci; 2022 Dec; 443():120459. PubMed ID: 36283150
[TBL] [Abstract][Full Text] [Related]
9. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis.
Baldwin KJ; Hogg JP
Curr Opin Neurol; 2013 Jun; 26(3):318-23. PubMed ID: 23493158
[TBL] [Abstract][Full Text] [Related]
10. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies.
Tavazzi E; Ferrante P; Khalili K
Clin Microbiol Infect; 2011 Dec; 17(12):1776-80. PubMed ID: 22082208
[TBL] [Abstract][Full Text] [Related]
11. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
Perkins MR; Ryschkewitsch C; Liebner JC; Monaco MC; Himelfarb D; Ireland S; Roque A; Edward HL; Jensen PN; Remington G; Abraham T; Abraham J; Greenberg B; Kaufman C; LaGanke C; Monson NL; Xu X; Frohman E; Major EO; Douek DC
PLoS Pathog; 2012; 8(11):e1003014. PubMed ID: 23144619
[TBL] [Abstract][Full Text] [Related]
12. The risk of progressive multifocal leukoencephalopathy under biological agents used in the treatment of chronic inflammatory diseases.
Toussirot É; Bereau M
Inflamm Allergy Drug Targets; 2014; 13(2):121-7. PubMed ID: 24559124
[TBL] [Abstract][Full Text] [Related]
13. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab: risk stratification of individual patients with multiple sclerosis.
Tur C; Montalban X
CNS Drugs; 2014 Jul; 28(7):641-8. PubMed ID: 24942634
[TBL] [Abstract][Full Text] [Related]
15. JCV detection in multiple sclerosis patients treated with natalizumab.
Sadiq SA; Puccio LM; Brydon EW
J Neurol; 2010 Jun; 257(6):954-8. PubMed ID: 20052484
[TBL] [Abstract][Full Text] [Related]
16. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.
Bellizzi A; Nardis C; Anzivino E; Rodìo D; Fioriti D; Mischitelli M; Chiarini F; Pietropaolo V
J Neurovirol; 2012 Feb; 18(1):1-11. PubMed ID: 22290500
[TBL] [Abstract][Full Text] [Related]
17. Progressive multifocal leukoencephalopathy.
Berger JR
Curr Neurol Neurosci Rep; 2007 Nov; 7(6):461-9. PubMed ID: 17999891
[TBL] [Abstract][Full Text] [Related]
18. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
19. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
[TBL] [Abstract][Full Text] [Related]
20. Lack of specific T- and B-cell clonal expansions in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
Bertoli D; Sottini A; Capra R; Scarpazza C; Bresciani R; Notarangelo LD; Imberti L
Sci Rep; 2019 Nov; 9(1):16605. PubMed ID: 31719595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
